CytoSorbents Corporation (CTSO)

[techxen]

The Hemodefend trial will thankfully be more straightforward with clear protocols. Unless this is a misprint - 2 sites and 20 patients.

From the Q2 2018 transcript:

"We expect to start the trial in Q1 2019. In terms of the study, it
is a fairly well-defined process for these types of blood filters. We still need to negotiate and receive approval for the trial design, but based on preliminary discussions, we believe it will be two sites and roughly 20 healthy volunteers to complete the trial. Compared to some of the things that Eric is working on, this is relatively straightforward from a clinical trial standpoint and is very well-defined by the agency (FDA)".

The September investor presentation however states Q2 2019. The company historically does not have a good track record with targets, things always take longer than expected so it more than likely will be late Q2 of next year before the trial starts.